Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203735032> ?p ?o ?g. }
- W3203735032 endingPage "1020" @default.
- W3203735032 startingPage "1020" @default.
- W3203735032 abstract "Metastatic castration-resistant prostate cancer (CRPC) has a five-year survival rate of 28%. As histone deacetylases (HDACs) are overexpressed in CRPC, the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) was trialled in CRPC patients but found to be toxic and inefficacious. Previously, we showed that novel HDAC inhibitors (Jazz90 (N1-hydroxy-N8-(4-(pyridine-2-carbothioamido)phenyl)octanediamide) and Jazz167 ([chlorido(η5-pentamethylcyclopentadieny[1-4](N1-hydroxy-N8-(4-(pyridine-2-carbothioamido-κ2N,S)phenyl)octanediamide)rhodium(III)] chloride) had a higher cancer-to-normal-cell selectivity and superior anti-angiogenic effects in CRPC (PC3) cells than SAHA. Thus, this study aimed to further investigate the efficacy and toxicity of these compounds. HUVEC tube formation assays revealed that Jazz90 and Jazz167 significantly reduced meshes and segment lengths in the range of 55-88 and 43-64%, respectively. However, Jazz90 and Jazz167 did not affect the expression of epithelial-to-mesenchymal transitioning markers E-cadherin and vimentin. Jazz90 and Jazz167 significantly inhibited the growth of PC3 and DU145 spheroids and reduced PC3 spheroid branching. Jazz90 and Jazz167 (25, 50 and 75 mg/kg/day orally for 21 days) were non-toxic in male BALB/c mice. The efficacy and safety of these compounds demonstrate their potential for further in vivo studies in CRPC models." @default.
- W3203735032 created "2021-10-11" @default.
- W3203735032 creator A5002306992 @default.
- W3203735032 creator A5025590518 @default.
- W3203735032 creator A5053047529 @default.
- W3203735032 creator A5078561219 @default.
- W3203735032 creator A5086697134 @default.
- W3203735032 creator A5087288813 @default.
- W3203735032 date "2021-10-04" @default.
- W3203735032 modified "2023-10-16" @default.
- W3203735032 title "Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer" @default.
- W3203735032 cites W1481966521 @default.
- W3203735032 cites W1487307409 @default.
- W3203735032 cites W1545484184 @default.
- W3203735032 cites W1931084569 @default.
- W3203735032 cites W1973588440 @default.
- W3203735032 cites W1979343637 @default.
- W3203735032 cites W1986581600 @default.
- W3203735032 cites W2006734059 @default.
- W3203735032 cites W2016348011 @default.
- W3203735032 cites W2030403720 @default.
- W3203735032 cites W2031627452 @default.
- W3203735032 cites W2031671750 @default.
- W3203735032 cites W2042580590 @default.
- W3203735032 cites W2055023167 @default.
- W3203735032 cites W2071405989 @default.
- W3203735032 cites W2087866158 @default.
- W3203735032 cites W2101284441 @default.
- W3203735032 cites W2104107345 @default.
- W3203735032 cites W2104337841 @default.
- W3203735032 cites W2119975980 @default.
- W3203735032 cites W2132682917 @default.
- W3203735032 cites W2142325703 @default.
- W3203735032 cites W2147984855 @default.
- W3203735032 cites W2149379768 @default.
- W3203735032 cites W2151136390 @default.
- W3203735032 cites W2156363416 @default.
- W3203735032 cites W2156876163 @default.
- W3203735032 cites W2159368077 @default.
- W3203735032 cites W2171580989 @default.
- W3203735032 cites W2175192779 @default.
- W3203735032 cites W2216326174 @default.
- W3203735032 cites W2256180276 @default.
- W3203735032 cites W235826207 @default.
- W3203735032 cites W2500581699 @default.
- W3203735032 cites W2521317541 @default.
- W3203735032 cites W2556399751 @default.
- W3203735032 cites W2588635793 @default.
- W3203735032 cites W2591580144 @default.
- W3203735032 cites W2762381618 @default.
- W3203735032 cites W2765609679 @default.
- W3203735032 cites W2773709858 @default.
- W3203735032 cites W2784541983 @default.
- W3203735032 cites W2791152362 @default.
- W3203735032 cites W2802868810 @default.
- W3203735032 cites W2891654049 @default.
- W3203735032 cites W2900889949 @default.
- W3203735032 cites W2913565730 @default.
- W3203735032 cites W2921313848 @default.
- W3203735032 cites W2937483840 @default.
- W3203735032 cites W2947913598 @default.
- W3203735032 cites W2982051641 @default.
- W3203735032 cites W3003450039 @default.
- W3203735032 cites W3015998993 @default.
- W3203735032 cites W3036283383 @default.
- W3203735032 cites W3043668595 @default.
- W3203735032 cites W3110288896 @default.
- W3203735032 cites W3125898896 @default.
- W3203735032 cites W4235193044 @default.
- W3203735032 doi "https://doi.org/10.3390/ph14101020" @default.
- W3203735032 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8540814" @default.
- W3203735032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34681244" @default.
- W3203735032 hasPublicationYear "2021" @default.
- W3203735032 type Work @default.
- W3203735032 sameAs 3203735032 @default.
- W3203735032 citedByCount "6" @default.
- W3203735032 countsByYear W32037350322022 @default.
- W3203735032 countsByYear W32037350322023 @default.
- W3203735032 crossrefType "journal-article" @default.
- W3203735032 hasAuthorship W3203735032A5002306992 @default.
- W3203735032 hasAuthorship W3203735032A5025590518 @default.
- W3203735032 hasAuthorship W3203735032A5053047529 @default.
- W3203735032 hasAuthorship W3203735032A5078561219 @default.
- W3203735032 hasAuthorship W3203735032A5086697134 @default.
- W3203735032 hasAuthorship W3203735032A5087288813 @default.
- W3203735032 hasBestOaLocation W32037350321 @default.
- W3203735032 hasConcept C104317684 @default.
- W3203735032 hasConcept C121608353 @default.
- W3203735032 hasConcept C126322002 @default.
- W3203735032 hasConcept C147447768 @default.
- W3203735032 hasConcept C150903083 @default.
- W3203735032 hasConcept C185592680 @default.
- W3203735032 hasConcept C204232928 @default.
- W3203735032 hasConcept C207001950 @default.
- W3203735032 hasConcept C2776438761 @default.
- W3203735032 hasConcept C2778305200 @default.
- W3203735032 hasConcept C2779723316 @default.
- W3203735032 hasConcept C2780192828 @default.